FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146848625> ?p ?o ?g. }

• W2146848625 endingPage "333" @default.
• W2146848625 startingPage "327" @default.
• W2146848625 abstract "Objective First, to investigate the overall efficacy and safety of rituximab (RTX) in refractory granulomatosis with polyangiitis (GPA) in a tertiary referral centre. Second, to compare the efficacy of RTX in granulomatous and vasculitic manifestations in GPA. Patients and methods This study comprised a retrospective, standardised data collection from all patients who received RTX for refractory Wegener's granulomatosis from 2002 to 2010. Patients were assessed by a standardised interdisciplinary diagnostic procedure (including ear, nose and throat and ophthalmology assessment, MRI, immunodiagnostics, B-cell levels and Birmingham Vasculitis Activity Score) and were treated by standardised therapeutic regimens according to available evidence. Results 59 patients received 75 cycles of RTX. 9.3% achieved complete remission. A response was documented in 61.3% (improvement in 52%, unchanged disease activity in 9.3%), 26.7% had refractory disease. Birmingham Vasculitis Activity Score, disease extent index, erythrocyte sedimentation rate, C-reactive protein and prednisolone demand decreased significantly. All patients achieved B-cell depletion. Granulomatous manifestations such as orbital granuloma and pachymeningitis were more frequently refractory to RTX than vasculitis or other granulomatous manifestations. Thus, for example, complete remission/improvement was found in 89.2% of patients with renal disease and in only 44.4% of those with orbital masses (p=0.003). The relapse rate was 44.4% after a median period of 13.5 months. Adverse events occurred in 29%, pneumonia in 15% and death in 3%. Conclusion The overall response rate of refractory GPA to RTX was high (61.3% complete remission or improvement). Response rates of vasculitic manifestations were excellent; failure of response/progress was mostly due to granulomatous manifestations, especially orbital masses. Relapse rates were high (40%) despite maintenance treatment." @default.
• W2146848625 created "2016-06-24" @default.
• W2146848625 creator A5016864652 @default.
• W2146848625 creator A5019339885 @default.
• W2146848625 creator A5023283683 @default.
• W2146848625 creator A5031865300 @default.
• W2146848625 creator A5035337350 @default.
• W2146848625 creator A5057094538 @default.
• W2146848625 creator A5071896130 @default.
• W2146848625 creator A5075130510 @default.
• W2146848625 date "2011-10-21" @default.
• W2146848625 modified "2023-09-30" @default.
• W2146848625 title "Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations" @default.
• W2146848625 cites W118889791 @default.
• W2146848625 cites W1897193160 @default.
• W2146848625 cites W1972057477 @default.
• W2146848625 cites W1974870063 @default.
• W2146848625 cites W1990393482 @default.
• W2146848625 cites W1992270926 @default.
• W2146848625 cites W2001824449 @default.
• W2146848625 cites W2002904469 @default.
• W2146848625 cites W2011309580 @default.
• W2146848625 cites W2011557149 @default.
• W2146848625 cites W2014437885 @default.
• W2146848625 cites W2023473273 @default.
• W2146848625 cites W2024564671 @default.
• W2146848625 cites W2024930078 @default.
• W2146848625 cites W2037162457 @default.
• W2146848625 cites W2038481132 @default.
• W2146848625 cites W2051521438 @default.
• W2146848625 cites W2057194530 @default.
• W2146848625 cites W2063340779 @default.
• W2146848625 cites W2071333258 @default.
• W2146848625 cites W2071865834 @default.
• W2146848625 cites W2084056567 @default.
• W2146848625 cites W2100809783 @default.
• W2146848625 cites W2102133319 @default.
• W2146848625 cites W2109207289 @default.
• W2146848625 cites W2120427700 @default.
• W2146848625 cites W2127258004 @default.
• W2146848625 cites W2129862573 @default.
• W2146848625 cites W2157081456 @default.
• W2146848625 cites W2163783808 @default.
• W2146848625 cites W2171950933 @default.
• W2146848625 cites W2264075806 @default.
• W2146848625 cites W2397545297 @default.
• W2146848625 cites W2409504934 @default.
• W2146848625 doi "https://doi.org/10.1136/ard.2011.153601" @default.
• W2146848625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22021864" @default.
• W2146848625 hasPublicationYear "2011" @default.
• W2146848625 type Work @default.
• W2146848625 sameAs 2146848625 @default.
• W2146848625 citedByCount "155" @default.
• W2146848625 countsByYear W21468486252012 @default.
• W2146848625 countsByYear W21468486252013 @default.
• W2146848625 countsByYear W21468486252014 @default.
• W2146848625 countsByYear W21468486252015 @default.
• W2146848625 countsByYear W21468486252016 @default.
• W2146848625 countsByYear W21468486252017 @default.
• W2146848625 countsByYear W21468486252018 @default.
• W2146848625 countsByYear W21468486252019 @default.
• W2146848625 countsByYear W21468486252020 @default.
• W2146848625 countsByYear W21468486252021 @default.
• W2146848625 countsByYear W21468486252022 @default.
• W2146848625 countsByYear W21468486252023 @default.
• W2146848625 crossrefType "journal-article" @default.
• W2146848625 hasAuthorship W2146848625A5016864652 @default.
• W2146848625 hasAuthorship W2146848625A5019339885 @default.
• W2146848625 hasAuthorship W2146848625A5023283683 @default.
• W2146848625 hasAuthorship W2146848625A5031865300 @default.
• W2146848625 hasAuthorship W2146848625A5035337350 @default.
• W2146848625 hasAuthorship W2146848625A5057094538 @default.
• W2146848625 hasAuthorship W2146848625A5071896130 @default.
• W2146848625 hasAuthorship W2146848625A5075130510 @default.
• W2146848625 hasConcept C121332964 @default.
• W2146848625 hasConcept C126322002 @default.
• W2146848625 hasConcept C141071460 @default.
• W2146848625 hasConcept C142424586 @default.
• W2146848625 hasConcept C2776015282 @default.
• W2146848625 hasConcept C2776715498 @default.
• W2146848625 hasConcept C2778143017 @default.
• W2146848625 hasConcept C2778910314 @default.
• W2146848625 hasConcept C2779134260 @default.
• W2146848625 hasConcept C2779338263 @default.
• W2146848625 hasConcept C2780653079 @default.
• W2146848625 hasConcept C2781229154 @default.
• W2146848625 hasConcept C71924100 @default.
• W2146848625 hasConcept C87355193 @default.
• W2146848625 hasConcept C90924648 @default.
• W2146848625 hasConceptScore W2146848625C121332964 @default.
• W2146848625 hasConceptScore W2146848625C126322002 @default.
• W2146848625 hasConceptScore W2146848625C141071460 @default.
• W2146848625 hasConceptScore W2146848625C142424586 @default.
• W2146848625 hasConceptScore W2146848625C2776015282 @default.
• W2146848625 hasConceptScore W2146848625C2776715498 @default.
• W2146848625 hasConceptScore W2146848625C2778143017 @default.
• W2146848625 hasConceptScore W2146848625C2778910314 @default.
• W2146848625 hasConceptScore W2146848625C2779134260 @default.

• next